Generate Life Sciences has acquired the Cell Care Group
July 27, 2021
Generate Life Sciences, a globally leading, family-focused life sciences company, announced the acquisition of the Cell Care Group. Located across Australia and Canada, the Cell Care Group is the premier provider of private blood banking in its markets.
Cain Brothers was engaged to serve as Generate Life Sciences’ financial advisor based on its deep domain expertise and long-standing relationship with both Generate and GI Partners.
The Cell Care international cord blood banking group is comprised of Cell Care in Australia as well as Insception Lifebank and Cells for Life in Canada. Cell Care is the only private cord blood bank in Australia while the Cell Care Group’s Canadian brands (Insception Lifebank and Cells for Life) have the leading market share of private cord blood banking in Canada. The combined group is one of the world’s top 10 companies in the sector with more than 200,000 cord blood and tissue samples stored.
Generate Life Sciences, a portfolio company of GI Partners, focuses on helping grow and protect families through newborn stem cell, genetic screening, medical device, and healthcare technology services. Generate serves over 1,200 IVF clinics annually and holds the largest catalogs of sperm and egg donors in the industry. The acquisition expands the operational footprint of Generate across three countries, alongside its distribution network for frozen donor gametes in more than 40 countries.
GI Partners is a private investment firm with offices in San Francisco, New York, Greenwich, Chicago and Scottsdale. The firm has raised over $28 billion in capital from leading institutions around the world to invest in its private equity, real estate, and data infrastructure strategies. The firm’s private equity arm invests in the Healthcare, IT Infrastructure, Services and Software sectors with a focus on North American middle market companies.
For more information, please contact: